SCHEMBL1013138

SCHEMBL1013138

ClCc1cccc(Oc2ncc(Br)cn2)c1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 5/20 0.40
KMT2A Q03164 5/20 0.40
HTT P42858 1/20 0.40
MAOB P27338 6/20 0.39
NPC1 O15118 1/20 0.36
GAA P10253 1/20 0.36
RAB9A P51151 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
CYP1A2 P05177 4/20 0.36
CYP3A4 P08684 4/20 0.36
CYP2C9 P11712 4/20 0.36
CYP2C19 P33261 4/20 0.36
ALDH1A1 P00352 3/20 0.36
USP2 O75604 3/20 0.36
CYP2D6 P10635 2/20 0.36
HPGD P15428 2/20 0.36
HPGDS O60760 1/20 0.36
TSHR P16473 3/20 0.35
HIF1A Q16665 1/20 0.35
CLK4 Q9HAZ1 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27209673 0.84 MEN1 (0.50) MEN1KMT2AHTTNPC1GAA
SCHEMBL1010905 0.84 NR1H2 (0.42) MEN1KMT2AHTTMAOBSMN1; SMN2
SCHEMBL30657586 0.83 MEN1 (0.49) MEN1KMT2AHTTNPC1GAA
SCHEMBL27094840 0.83 MEN1 (0.49) MEN1KMT2AHTTNPC1GAA
SCHEMBL1011671 0.82 ALDH1A1 (0.41) MEN1KMT2AHTTMAOBCYP1A2
SCHEMBL22405019 0.79 MEN1 (0.50) MEN1KMT2AHTTNPC1GAA
SCHEMBL4188638 0.79 GPBAR1 (0.40) MAOBSMN1; SMN2TSHRTTR
SCHEMBL11309725 0.78 MAOB (0.53) MAOBNPC1RAB9ASMN1; SMN2ALDH1A1
SCHEMBL18422515 0.77 TTR (0.46) MEN1KMT2AHTTMAOBGAA
SCHEMBL11313737 0.77 MAPT (0.42) MEN1KMT2AHTTMAOBGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8044052-B2 Inhibitors of fatty acid amide hydrolase; N-pyridin-3-yl-4-(3-{[5-(trifluoromethyl)pyridin-2-yl]oxy}benzylidene)piperidine-1-carboxamide; elevate brain anandamide levels; pain, urinary incontinence, cognitive disorders, anxiety, depression, sleeping, eating, movement disorders, glaucoma, psoriasis PFIZER INC. (US) 2011-10-25 US disclosed
EP-2076508-B1 BIARYL ETHER UREA COMPOUNDS PFIZER PROD INC (US) 2011-01-05 EP disclosed
EP-2076508-A2 BIARYL ETHER UREA COMPOUNDS Pfizer Products Inc. (US) 2009-07-08 EP disclosed
US-20080261941-A1 Biaryl Ether Urea Compounds Jazz Pharmaceuticals Therapeutics, Inc. 2008-10-23 US disclosed
WO-2008047229-A2 BIARYL ETHER UREA COMPOUNDS PFIZER PRODUCTS INC. (US) 2008-04-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080261941-A1 Biaryl Ether Urea Compounds FAAH, FAAH2, LIPC MEN1 4102/4885KMT2A 1650/4885HTT 2531/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.